NeuroSense Therapeutics

About:

NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for ALS.

Website: https://www.neurosense-tx.com/

Top Investors: PipelBiz.com

Description:

NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Total Funding Amount:

$10.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Herzliya, Tel Aviv, Israel

Founded Date:

2017-01-01

Contact Email:

info(AT)neurosense-tx.com

Founders:

Alon Ben-Noon

Number of Employees:

11-50

Last Funding Date:

2024-08-06

IPO Status:

Public

Industries: